从盾叶鬼臼中分离内生真菌用于生产鬼臼毒素

作者从盾叶鬼臼Podophyllum peltatum Wang ＆ Wilcom的根茎中分离出内生真菌Phialocephalafortinii（一种食用菌）PPE5和PPE7株。经过4周的培养，这2株真菌在肉汤培养基中可产生鬼臼毒素。     

含鞣质的余甘子提取物制剂用于治疗由抗结核药诱导的细胞色素P450活化引起的肝毒性

US2006121138-A1该制剂是由余甘子Emblica officinalis提取物和添加剂以及载体、赋形剂、稀释剂或溶剂组成。余甘子用水、水-乙醇或乙醇等极性溶剂室温提取15~25h,得到含鞣质8.5%~15%的提取物。添加剂是一种营养剂,由蛋白质、碳水化合物、糖类、滑石粉、硬脂酸镁、纤维素、碳酸钙或淀粉-明胶胶体组成。提取物和添加剂的比例为1∶1~1∶10。本品用于治疗由至少一种抗结核药(利福平、吡嗪酰胺或异烟肼)引起的CYP450活化的肝中毒,恢复肝功能至正常,但对不依赖于CYP450生物活化的肝毒性无效。本品通过在血清或肝中多细胞色素异构体活化来对抗…     

对急性脑卒中患者进行早期系统康复治疗的研究

目的:探讨早期系统康复治疗对急性脑卒中患者偏瘫肢体运动功能和日常生活活动能力的影响.方法:80例急性脑卒中患者随机分组并对康复组采用早期系统康复治疗,于治疗前后用Fugl-Mayer法、Barthel指数评定两组患者偏瘫肢体运动功能和日常生活活动能力.结果:治疗前两组Fugl-Mayer值及Barthel指数评分差异不显著(P＞0.05);治疗后(1个月和6个月),康复组Fugl-Mayer值、Barthel指数评分均明显高于对照组,具有显著性差异(P＜0.01).结论:早期系统、规范康复治疗的介入,能促进急性脑卒中患者神经功能恢复,提高生存质量.     

含乌司他丁肺保护液在心肺转流术中的肺保护作用

Objective To evaluate protective effects of hypothermic pulmonary protective solution with uli-nastatin on lung function during cardiopulmouary bypass (CPB) in the patients with congenital heart disease(CHD) and pulmonary hypertenion. Method Fifty-four children,who had CHD of left-to-fight shunts with moderate-se-rious pulmonary hypertension, were enrolled. They had been performed with the radical operation under CPB from September 2005 to December 2006 in the Department of Cardiovascular Surgery, Children' s Hospital of Zhejiang University. Moderate-serious pulmonary hypertension was defined as pulmonary-to-systolic pressure ratio > 0.45(Pp/Ps > 0.45). Fifty-four children were randomly divided into three groups. Patients in group A (n = 18)didn't receive pulmonary protective solution, and scrved as control; patients in group B (n = 18) were adminis-tered with pulmonary protective solution without ulinastatin;patients in group C (n = 18) were administered with pulmonary protective solution with ulinastatin. The serum concentrations of MDA and MPO were measured at five different time points:pre-operation, 0 h, 3 h, 6 h and 24 h in the intensive care unit (ICU) (T1～5). Patients'lung functions were monitored at T1 - T4. The time of mechanical ventilation was recorded. Results No one died in this study. The mean time of mechanical ventilation was shorter in the group B and group C than that in the group A. The MDA and MPO levels were lower in group B compared with group A at T4. The MDA level at T3-T5 and the MPO level at T4 was lower in group C than those in group A. There were no significant in MDA and MPO levels between group B and group C at five time point.A-aDO2 was lower in groups B and C than those in group A at T3 and T4, whereas at T4, A-aDO2 was lower in group C than that in group B. Cdyn was higher in group B at T3and group C at T3 - T4 than those in group A. Cdyn was lower in groups C than that in group B at T4.Condusions Lung perfusion with hypothermic protective solution during CPB can all lung injury and promote recovery after operation, especialy with ulinastatin.     

药物洗脱支架治疗左乳内动脉桥血管病变的临床研究

目的:评价药物洗脱支架(DES)治疗左乳内动脉(LIMA)桥血管病变的临床效果。方法:回顾性分析从2004年5月到2006年5月我院对LIMA桥血管病变连续行经皮冠状动脉介入治疗(PCI)13例患者。结果:患者基线特点:年龄(57.5±10.2)岁;男性10例(76.9%);既往心肌梗死8例(61.5%);既往PCI7例(53.8%);糖尿病6例(46.2%);左心室射血分数0.466±0.312。病变基线特点:远端吻合口12例(92.3%);体部1例(7.7%)。参照血管直径(2.95±0.47)mm;病变长度(14.0±14.6)mm。置入DES100%;支架直径(2.92±0.49)mm;支架长度(18.8±6.2)mm;支架释放压力(13.5±2.5)atm。介入成功率100%。所有患者完成6个月临床随访,有3例完成造影随访。主要心脏不良事件0%;无死亡、急性心肌梗死、靶血管再血管化治疗。有3例患者因非靶病变再次行PCI治疗。结论:DES治疗LIMA桥血管病变是安全可行的。     

HPLC法测定当归四逆汤中芍药苷的含量

目的 　建立 HPLC测定当归四逆汤中芍药苷的定量方法。 方法 　以反相高效液相法测定芍药苷的含量。固定相 :Shimpack CL C-ODS(15 0 mm× 6mm) ,流动相 :乙腈 -0 .1%磷酸水溶液 (17∶ 83 ) ,检测波长 :2 3 0 nm。 结果 　芍药苷在 9.1-91μg· m L- 1范围内线性良好 (r=0 .9999) ,平均加样加收率为 10 0 .3 6% ,RSD为 1.91%。 结论 　该方法简便准确 ,专属性强 ,能满足该制剂质量标准的要求。     

药物洗脱支架治疗支架内再狭窄的对照研究

目的 比较3种药物洗脱支架(DES)治疗支架内再狭窄的长期临床效果.方法 回顾性分析阜外医院对支架内再狭窄病例用DES行经皮冠状动脉介入治疗(PCI)的390例患者,其中雷帕霉素药物洗脱支架(Cypher)组187例(C组),紫杉醇药物涂层支架(Taxus)组89例(T组),国产雷帕霉素涂层支架(Firebird)组114例(F组).结果 T组不稳定性心绞痛比率高于另2组,F组左主干病变比率低于另2组,而3支病变比率高于另2组.3组平均临床随访时间为864、848和719 d,主要不良心脏事件发生率差异无统计学意义(P=0.081),3组总的支架内血栓发生率差异无统计学意义(P=0.605).7个月造影随访支架内和血管段再狭窄率T组有增高的趋势(17.9%比29.4%比13.6%.P=0.214和21.8%比35.3%比15.9%,P=0.132).支架内和血管段的晚期丢失T组均明显大于另外2组[(0.31±0.12)mm比(0.75±0.24)mm比(0.31±0.13)mm,P=0.000和(0.33±0.18)mm比(0.61±0.23)mm比(0.31±0.14)mm,P=0.001].结论 3种DES治疗支架内再狭窄病变的长期疗效相似,Cypher和Firebird抑制内膜增生的作用更强.     

亚甲基四氢叶酸还原酶基因C677T多态性与先兆型偏头痛相关性的Meta分析

目的探讨亚甲基四氢叶酸还原酶(MTHFR)基因C677T多态性与先兆型偏头痛(MA)的相关性。方法检索1994年1月~2013年3月MEDLINE、EBSCO、EMBASE数据库及PubMed,以及中国医院知识仓库中文期刊全文库、中国生物医学文献数据库、维普、万方等中文数据库中关于MTHFR基因C677T多态性与MA相关性的文献,按纳入、排除标准选择文献,并采用RevMan 5软件进行Meta分析。结果共纳入18项病例对照研究,其中MA患者4276例,对照者27979例。各研究间具有很强的异质性(P0.05,I2=72%),采用随机效应模型分析。Meta分析显示,MTHFR基因TT基因型发生MA的风险明显高于CT+CC基因型(OR=1.33,95%CI:1.02~1.75,P0.01)。剔除不符合H-W遗传平衡定律的3篇文献后,总的分析结果依然稳定(OR=1.39,95%CI:1.02~1.88,P0.01)。在MA人群中所做种族分层分析结果显示,在地中海人种TT基因型增加了MA的发病风险,而在其他高加索人(包括北欧人种和印度雅利安人种)、芬兰人、土耳其人及日本人的研究并未显示出这种相关性。结论 MTHFR基因C677T多态性与MA相关,其TT基因型个体MA发病的风险增加。这在不同种族间存在一定差别。     

入院糖化血红蛋白水平对行经皮冠状动脉介入治疗的无糖尿病病史患者远期预后的影响

目的:探讨入院糖化血红蛋白(HbA1C)水平对行经皮冠状动脉介入治疗(PCI)的无糖尿病病史患者临床远期预后的影响。方法:纳入2013年1月至12月在我院行PCI的无糖尿病病史的冠心病患者6944例。根据入院HbA1C水平分为三组:HbA1C<5.7%组、HbA1C 5.7%~6.4%组和HbA1C≥6.5%组。2年随访的主要终点为主要不良心血管事件(MACE),包括死亡、再次心肌梗死和血运重建。分析入院HbA1C水平对行PCI的无糖尿病病史患者临床远期预后的影响。结果:在6944例行PCI的无糖尿病病史患者中,HbA1C<5.7%组1302例(18.75%),HbA1C 5.7%~6.4%组4344例(62.56%),HbA1C≥6.5%组1298例(18.69%)。2年随访结果显示,HbA1C≥6.5%组和HbA1C 5.7%~6.4%组的MACE发生率显著高于HbA1C<5.7%组(11.0%vs 10.5%vs 8.4%,P=0.047)。多因素分析显示:HbA1C 5.7%~6.4%组和HbA1C≥6.5%组发生MACE风险分别是HbA1C<5.7%组的1.262倍(95%CI:1.022~1.559,P=0.031)和1.304倍(95%CI:1.010~1.682,P=0.041)。结论:在接受PCI的无糖尿病病史的冠心病患者中,入院HbA1C水平是2年MACE发生的独立预测因子。